The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Ravi Madan
Research Funding - Bayer
 
Esther Mena
No Relationships to Disclose
 
Liza Lindenberg
No Relationships to Disclose
 
Megan Hausler
No Relationships to Disclose
 
Monique Williams
No Relationships to Disclose
 
Amy Hankin
Stock and Other Ownership Interests - Amgen; Medtronic
 
Jeanny Aragon-Ching
Honoraria - Astellas Scientific and Medical Affairs Inc; Bristol-Myers Squibb; EMD Serono; Merck KGaA; Merck/Pfizer; Pfizer/EMD Serono
Consulting or Advisory Role - Algeta/Bayer; Amgen; AstraZeneca; AstraZeneca; AstraZeneca/MedImmune; AVEO; Bayer; Dendreon; EMD Serono; Exelixis; Immunomedics; Janssen Biotech; Merck; Novartis; Pfizer; Pfizer/Myovant; Sanofi; Seagen
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Janssen-Ortho; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Algeta/Bayer; Astellas Pharma; Bristol Myers Squibb; Dendreon; EMD Serono
 
Laura Sena
Research Funding - Panbela Therapeutics (Inst)
 
Russell Pachynski
No Relationships to Disclose
 
Edwin Posadas
Consulting or Advisory Role - Bayer
Speakers' Bureau - Bayer
Research Funding - EnviroTherapetuics, Inc (Inst); PFizer (Inst)
Patents, Royalties, Other Intellectual Property - Patent on NanoVelcro Assay for CTCs in prostate cancer
Expert Testimony - Shook, Hardy & Bacon L.L.P.
 
Helen Moon
Honoraria - EMD Serono (Inst); EMD Serono/Merck (Inst); Pfizer/EMD Serono (Inst); Pfizer/NCCN (Inst)
Research Funding - Amgen (Inst); Apollomics (Inst); Arcus Biosciences (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); HUYA Bioscience International (Inst); Merck (Inst); Nektar (Inst); Pfizer (Inst); Prometheus; Revimmune (Inst); Seagen (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Aveo; Bayer; Genentech; Pfizer; Seagen
 
Marijo Bilusic
Research Funding - Bicycle Therapeutics (Inst); Hookipa Biotech (Inst); Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Proviva Therapeutics (Inst); Surface Oncology (Inst)
 
Catherine Marshall
Honoraria - OncLive/MJH Life Sciences; Tempus
Consulting or Advisory Role - Bayer; Dendreon; McGraw-Hill Education; Obseva; Pfizer
Research Funding - AstraZeneca (Inst)
Patents, Royalties, Other Intellectual Property - McGraw Hill - textbook royalties
Travel, Accommodations, Expenses - Bayer; DAVA Pharmaceuticals
 
Katherine Lee-Wisdom
No Relationships to Disclose
 
Deborah Jolissaint
No Relationships to Disclose
 
Gregory Chestnut
No Relationships to Disclose
 
William Figg
Research Funding - Astellas Pharma (Inst); Biocompatibles (Inst); Celgene (Inst); Nerviano Medical Sciences (Inst); NovaRX (Inst); Pfizer (Inst); Propella Therapeutics (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Aryl Hydantoin Hetercycles and Methods of Making and Using Thereof NIH and HHS Reference No. E-169-2018-0 US Provisional Application filed in 2019 License to Novartis Institutes for BioMedical Research (Inst); Aza-Epoxy-guaiane Derivatives and Treatment of Cancer NIH and HHS Reference No. E-090-2014/2-US-05) European Patent No. 3102581, filed 05/02/2018 U.S. Provisional Patent Application No. 62/018,381, filed 06/27/2014 PCT Application No. PCT/US2015/014601 (Inst); Epidithiodiketopiperazine Analogs and Methods of Use NIH and HHS Reference No. E-089-2023-0-PC-01 U.S. PCT Patent Application No. PCT/US2024/032744, filed 06/06/2024 (Inst); Hypoxia Inducible Factor 1 (HIF-1) Inhibitors NIH and HHS Reference No. E-115-2015/0-US-01 U.S. Provisional Application No. 62/144,182 filed 04/07/2015 U.S. Patent No. 10,246,463 issued 4/2/2019 (Inst); SLCO1B3 genotype NIH and HHS Reference No.: E-083-2007/0-EIR-00) US Provisional Application No.: 60/879,503 (E-083-2007/0-US-01) Filed application provisional 01/08/2007 PCT Appliciaton: PCT/US2008/000310 Filed application international 01/08/2008 Nati (Inst); Thalidomide Analogs and Methods of Use NIH and HHS Reference No. E-208-2015/0-US-01 U.S. Patent Application No 62/235,105, filed 09/30/2015 U.S. Patent Application No. 15/765,193, filed 03/28/2018 Patent No. 10,730,835 (USA, Australia, Canada, Europe, (Inst); Thalidomide Analogs and Methods of Use NIH and HHS Reference No. E-208-2015/0-US-01 U.S. Patent Application No 62/235,105, filed 09/30/2015 U.S. Patent Application No. 15/765,193, filed 03/28/2018 Patent No. 10,730,835 (USA, Australia, Canada, Europe, (Inst)
 
Fatima Karzai
No Relationships to Disclose
 
Peter Choyke
No Relationships to Disclose
 
Melissa Abel
No Relationships to Disclose